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Purpose
This systematic review focuses on the efficacy of LDL apheresis to prevent 
the onset or progression of CVD in patients with severe FH who are refractory 
to, or intolerant of, lipid-lowering drug therapy.  The following studies 
indicating the advantages of LDL apheresis on cardiovascular morbidity and 
mortality will be discussed: The Familial Hypercholesterolemia Regression 
Study (FHRS), the Japan Low-Density Lipoprotein Apheresis Coronary 
Atherosclerosis Prospective Study (L-CAPS), the Low-Density Lipoprotein 
Apheresis Coronary Morphology and Reserve Trial (LACMART), and the 
LDL Apheresis Atherosclerosis Regression Study (LAARS). The Grading of 
Recommendations Assessment, Development and Evaluation (GRADE) 
criteria will be applied to the four studies included in the review in order to 
assess the quality of evidence and strength of recommendations for the 
utilization of LDL apheresis. 
Method
An extensive literature search was performed in October through November 
of 2010 using the databases of PubMed, Endotext, Science Direct, and the 
journals of Cardiology in Review and The Journal of Clinical Lipidology. The 
key words searched included “low-density lipoprotein apheresis” and “familial 
hypercholesterolemia” individually and in various combinations.  Inclusion 
criteria consisted of full text articles in the English language pertinent to LDL 
apheresis and its effect on cardiovascular disease risk factors or events.  
Exclusion criteria consisted of articles describing the use of LDL apheresis in 
non-cardiovascular disease processes, articles older than 15 years, and study 
designs other than randomized, controlled trials, cohort and case control 
studies. In total, four articles pertinent to LDL apheresis and its effect on 
cardiovascular disease risk factors or events were selected for the current 
systematic review. 
Results
From this review, practitioners can ascertain that LDL apheresis drastically 
improves markers of CVD, namely LDLc, total cholesterol (TC), Lp(a), 
minimal lumen diameter (LD min), mean lumen diameter  (LD mean), plaque 
area (PA), mean segment diameter (MSD), minimal obstruction diameter 
(MOD), mean percent diameter stenosis of atherosclerotic lesions (% DS), and 
time to ST depression on echocardiogram during stress testing, in 
hypercholesterolemic patients who are non-responsive to anti-lipid drug 
therapy, diet, and lifestyle modifications. 
Discussion 
The clinical effects of LDL apheresis include arrest of progression of 
coronary stenosis, reduction of calcified plaque volume and plaque area, 
expansion of coronary reserve, and reduction of morbidity and mortality 
secondary to CVD. Thus, the primary treatment outcomes of LDL apheresis 
are evidenced to be regression and/or retardation of coronary atherosclerosis. 
Usually safe and well-tolerated, LDL apheresis is not without its 
shortcomings.  The mere delivery of apheresis treatment is limited by its 
expense, ranging from $2,000-$2,500 per treatment session.  Moreover, there 
are estimated to be less than 50 treatment centers within the entire United 
States.  Treatment time for the procedure may require up to four hours.  
Known side effects of apheresis are few, including fatigue and hypotension 
following a treatment cycle.  Antihypertensive medications must be avoided on 
the day of the apheresis treatment, specifically angiotensin-converting enzyme 
(ACE) inhibitors, as increased bradykinin levels during the procedure may 
instigate severe hypotension.
The frequency of, and need for, LDL apheresis depends on the response to 
treatment and the degree of hypercholesterolemia at baseline.  The post-
apheresis rebound in LDLc is determined by both the rate at which LDL 
particles are catabolized and the rate at which they are produced.  The rate of 
Introduction
Familial hypercholesterolemia (FH) is a genetic disorder of 
lipoprotein metabolism characterized by extremely high plasma 
concentrations of low-density lipoprotein cholesterol (LDLc), tendon 
xanthomas, and increased risk of premature cardiovascular disease 
(CVD).  Worldwide, over 10 million people are currently afflicted 
with FH.  If appropriate preventive efforts are not employed before 
the age of 65, approximately 85% of males and 50% of females will 
suffer a coronary event.  LDL apheresis is an efficacious method of 
decreasing LDLc concentrations in patients with FH who are either 
refractory to, or intolerant of, pharmacologic therapy.
LDL apheresis refers to the extracorporeal removal of circulating 
LDLc by plasma exchange or by more selective methods.  
Additionally, lipoprotein(a) [Lp(a)], triglycerides (TGs), high-density 
lipoprotein cholesterol (HDLc), and fibrinogen are eliminated to 
varying degrees.  A typical apheresis treatment session is as follows:  
The patient is seated, both arms extended to gain bilateral antecubital 
venous access.  Blood is removed from one arm, and is pumped 
through the apheresis circuit, where a column then separates plasma 
from other blood components via centrifugation or by the use of 
membranes.  The LDLc is eliminated and venous blood is returned to 
the body through the contralateral arm. At any given time during the 
procedure, less than one pint of blood circulates external to the body.  
A standard apheresis session lasts roughly three hours depending on 
the method utilized 
In the United States, LDL apheresis is approved for heterozygous 
FH patients with an LDLc > 300 mg/dL or > 200 mg/dL with known 
coronary artery disease (CAD), despite maximal pharmacologic 
therapy. For patients with homozygous FH, LDL apheresis may be 
proposed if LDLc level > 500 mg/dL.  Prior to approval for LDL 
apheresis, patients must fail six months of dietary therapy based on 
the American Heart Association guidelines and pharmacologic 
therapy with at least two separate classes of lipid-lowering 
medications.
Marked reductions in circulating lipoproteins and lipids may be 
possible through long-term therapy with LDL apheresis, 
substantially reducing the rate of future cardiovascular events in this 
high risk population.  Another tendency may be to neglect lipid-
lowering surgical procedures, namely partial ileal bypass surgery, 
portacaval shunt, and liver transplantation.
rebound LDLc reaches a plateau in FH heterozygotes in around 14 days and a similar plateau is reached in FH homozygotes in 
three to four weeks.  A single treatment session with LDL apheresis reduces LDLc concentration 70-80% from baseline in both 
heterozygotes and homozygotes.  LDLc promptly begins to rise following the procedure, necessitating repeat sessions at 
approximately seven to ten day intervals in patients with homozygous FH and two-week intervals in patients with severe 
heterozygous FH.  With regular apheresis treatments, long-term decreases are produced in the LDLc levels both pre-treatment 
and post-treatment.  In patients who derive even minimal benefit from lipid-lowering medications, diet and pharmacotherapy 
should be maintained to help reduce LDLc levels.  Figure 1 depicts a stylized rendition of the effect of LDL apheresis on LDLc 
levels over time.
GRADE provides healthcare practitioners sufficient information for making well-informed decisions, and subsequent clinical 
actions, regarding LDL apheresis.  This review assesses quality of evidence and strength of recommendations for the utilization 
of LDL apheresis to prevent judgment errors and facilitate improved communication on its implementation by providers. Refer 
to the GRADE Table delineating strength of evidence of LACMART, L-CAPS, LAARS, and FHRS.
Conclusion
The risk of a coronary event in patients with familial hypercholesterolemia is extremely high. Therefore, the ability to delay 
the onset or slow the progression of cardiovascular disease would provide a significant benefit.   LDL apheresis is an adjunctive 
therapy to lipid-lowering drugs, commanding a vital role in the prevention of cardiac events through restructuring and 
stabilization of coronary plaque. In addition to patients suffering from severe FH refractory to, or intolerant of, lipid-lowering 
drugs, LDL apheresis may be beneficial for patients with CVD at high risk of acute coronary syndrome. 
The quality of evidence and strength of recommendation of LDL apheresis to arrest further progression of CVD and induce 
regression of atherosclerotic plaque in patients with FH is moderate.  This recommendation holds true after the application of 
exhaustive criteria set forth by the Grading of Recommendations Assessment, Development and Evaluation Working Group.  Per 
the GRADE Working Group, with moderate quality of evidence further research is likely to have an important impact on the 
confidence in the estimate of effect and may change the estimate.  For this reason, studies of longer intervention periods are 
warranted to confirm these findings and observe the expected angiographic regression of CVD.  
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LACMART
(Matsuzaki et 
al., 2002)
RCT Aph + LL drugs LD min ↑
High 0 0 0 -1 0 0 0 0 Moderate Moderate
PAb ↓
TC ↓
LDLc ↓
Atherosclerosis Regression
LL drugs LD min ↓
PAb ↑
TC ↑
LDLc ↑
Atherosclerosis Stable, no regression
L-CAPS
(Daida & 
Yamaguchi, 
1997)
N 
RCT
Aph + simva40 LD min ↑
High 0 0 0 -1 0 0 0 0 Moderate Moderate
TC ↓
LDLc ↓
Atherosclerosis Regression
Simva40 + Co20 LD min ↓
TC ↓
LDLc ↓
Atherosclerosis Stable, no regression
LAARS 
(Kroon et al., 
1996)
RCT Aph + simva MSD None
High 0 0 0 -1 0 0 0 0 Moderate Moderate
MOD None
LDLc ↓
% DS Regression
ST depression ↓
Simva + resin MSD None
MOD None
LDLc ↓
% DS Regression
ST depression No change
FHRS 
(Kitano & 
Thompson, 
1997)
RCT Aph + Simva40 TC ↓
High 0 0 0 -1 0 0 0 0 Moderate Moderate
LDLc ↓
Lp(a) ↓
% DS No change
LD mean ↑
LD min ↑
Simva40 + Co20 TC ↓
LDLc ↓
Lp(a) ↑
% DS No change
LD mean ↓
LD min ↓
LACMART, Low-Density Lipoprotein Apheresis Coronary Morphology Reserve Trial; L-CAPS, Low-Density Lipoprotein Apheresis Coronary Atherosclerosis Prospective Study; LAARS, LDL Apheresis Atherosclerosis Regression Study; FHRS, Familial Hypercholesterolemia Regression 
Study; RCT, randomized controlled trial; NRCT, non-randomized, controlled trial;  Aph, apheresis; LL drugs, lipid-lowering drugs; LD min, minimal lumen diameter on CQA; CQA, coronary quantitative angiogram; LD mean, mean lumen diameter of atherosclerotic lesions PA b, plaque area 
on IVUS; IVUS, intravenous ultrasound; TC, total cholesterol; LDLc, low-density lipoprotein cholesterol; Simva40, simvastatin 40 mg; Co20, colestipol 20 mg; MSD, mean segment diameter; MOD, minimal obstruction diameter; % DS, mean percent diameter stenosis of atherosclerotic 
lesions; ST depression , time to ST depression on echocardiogram; Lp(a), lipoprotein(a)
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.  Stylized rendition of the effect of LDL apheresis on LDLc levels.  Note the decline in concentration status post  
treatment and return to near pre-treatment levels.  Over time, the LDLc level does not return to the original baseline.   
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